THERADIAG announced the launch of ez-Track, a real Point-of-Care Testing (POCT) solution for therapeutic drug monitoring. In search of increasingly patient-focused solutions while respecting quality standards, the global healthcare sector is considering more Point-of-Care Testing (POCT), which is becoming a potential alternative allowing quickly diagnosing a disease, reducing waiting times and speeding up the start of treatment. As a company focused on quality innovation, Theradiag is entering this market with the ez-Track1 system.

Marketed primarily in Europe for the time being under the Theradiag brand, ez-Track carries out tests as close as possible to patients due to whole blood samples (incl. capillary, i.e. from the fingertips). This ez-Track then provides the results of these tests within 10 minutes.

The usage of the system allows therefore a rapid decision; it will definitively accelerate the implementation of biotherapies monitoring. Compact, easy to use and compatible with all the kits developed by Theradiag, the ez-Track1 technological solution completes the Theradiag range of systems which was until now the Lisa Tracker and the i-Track. The system ez-Track is CE marked and this will enable a rapid launch activity.

The menu at launch is composed of Infliximab and anti-Infliximab, as well as Adalimumab, and anti-Adalimumab, all CE marked. The ez-Track1 test menu related to chronic inflammatory diseases and other diseases will further expand rapidly.